DUBLIN--(BUSINESS WIRE)--The "Vaso-Occlusive Crisis - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
A detailed picture of the Vaso-Occlusive Crisis pipeline landscape is provided which includes the disease overview and Vaso-Occlusive Crisis treatment guidelines.
The assessment part of the report embraces, in depth Vaso-Occlusive Crisis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vaso-Occlusive Crisis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Vaso-Occlusive Crisis Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Vaso-Occlusive Crisis targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available.
Vaso-Occlusive Crisis pipeline report covers 9+ companies. Some of the key players include Novartis (Crizanlizumab), Prolong Pharmaceuticals (Sanguinate) etc.
Scope of the report
- The Vaso-Occlusive Crisis report provides an overview of therapeutic pipeline activity for Vaso-Occlusive Crisis across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Vaso-Occlusive Crisis therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Vaso-Occlusive Crisis Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
-
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Vaso-Occlusive Crisis
Key Topics Covered:
1. Report Introduction
2. Vaso-Occlusive Crisis (Sickle cell crisis)
2.1. Vaso-Occlusive Crisis Disease Overview
2.2. Vaso-Occlusive Crisis History
2.3. Vaso-Occlusive Crisis Symptoms
2.4. Vaso-Occlusive Crisis Causes
2.5. Vaso-Occlusive Crisis Pathophysiology
2.6. Vaso-Occlusive Crisis Diagnosis
2.6.1. Diagnostic Guidelines
3. Vaso-Occlusive Crisis Current Treatment Patterns
3.1. Treatment Guidelines
4. Vaso-Occlusive Crisis- An Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Vaso-Occlusive Crisis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Vaso-Occlusive Crisis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
4.1.2.2. Vaso-Occlusive Crisis Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono/Combination)
4.2.3. Assessment by Route of Administration
4.2.4. Assessment by Molecule Type
4.2.5. Assessment by MOA
5. Vaso-Occlusive Crisis Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.3. Early Stage Products (Phase-I)
5.4. Pre-clinical and Discovery Stage Products
5.5. Inactive Products
6. Vaso-Occlusive Crisis-Products Analysis
6.1. Product Profiles
6.1.1. Crizanlizumab- Novartis
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Sanguinate- Prolong Pharmaceuticals
7. Recent Technologies
8. Vaso-Occlusive Crisis Key Companies
8.1. Novartis
8.2. CytRx Corporation
8.3. NuvOx Pharma
8.4. GlycoMimetics
8.5. Sancilio & Company
8.6. Global Blood Therapeutics
8.7. AstraZeneca
8.8. Pfizer
8.9. Prolong Pharmaceuticals
9. Vaso-Occlusive Crisis Key Products
9.1. Crizanlizumab
9.2. Vepoloxamer
9.3. NVX 508
9.4. Rivipansel
9.5. Docosahexaenoic acid
9.6. Voxelotor
9.7. Ticagrelor
9.8. Rivipansel
9.9. Sanguinate
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Vaso-Occlusive Crisis - Unmet Needs
12. Vaso-Occlusive Crisis - Future Perspectives
13. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2f0f7d
